Brussels takes over vaccine sales from the Netherlands, France and Germany | NOW

The deal the vaccine alliance of the Netherlands, Germany, France and Italy made with AstraZeneca for the supply of 300 to 400 million potential vaccines has been taken over by the European Commission (EC). That means less financial burden for the cabinet. Whether a smaller proportion of the vaccines will eventually go to the Netherlands is still the question.

A spokesperson for the Ministry of Health confirms this in conversation with

The vaccine from the pharmaceutical company AstraZeneca has not yet entered production. The drug must first go through a few clinical trials, during which the vaccine is tested on tens of thousands of participants for side effects and other health risks. Promising results were achieved in earlier research phases.

If the development of the vaccine goes well, it is possible that 300 to 400 million vaccines will gradually become available for Europe from the end of this year. The vaccines would be distributed based on population.

In mid-June, EC started collective surgery in the race for vaccine

The vaccine alliance invited other EU member states to join the four countries in order to create an even stronger negotiating position in the vaccine market. In the end, the European Commission announced in mid-June that it would henceforth come up with a collective European strategy to obtain a vaccine as one united party.

Deals largely consist of support for the pharmaceutical companies, which see their costs for the research and the final production being financed. In return, the paying party receives a large dose of vaccines. In this way, the risks of pharmaceutical companies are also covered.

The EC writes in a press release that use is made of the emergency fund (ESI), but does not specify the amount that will be paid for the delivery. President Ursula von der Leyen calls the deal “a possibility to later supply vaccines to all Europeans and partners”.


Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.